A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)Erica Brivio, C. Michel Zwaan, Marta López‐Yurda et al.|Blood|2020Cited by 93